# US 6,787,132 B1 · Combined chemo-immunotherapy with liposomal drugs and cytokines

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 6,787,132 B1
- Document ID: US6787132B1
- Status: Granted
- Kind: B1
- Application number: 09/555,674
- Filed: 2000-08-03
- Granted: 2004-09-07
- Earliest claimed: 1997-12-04
- Assignees: Yissum Research Development Company of the Hebrew University of Jerusalem; Hadasit Medical Research Services and Development Ltd.
- Inventors: Alberto A. Gabizon; Eliezer Kedar; Yechezkel Barenholz
- Web page: https://patentgrep.com/patent/US6787132B1

## CPC

- A61K 38/21: Interferons {[IFN]}
- A61K 9/1271: Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers (liposomes as conjugates {A61K47/6911})
- A61K 38/193: {Colony stimulating factors [CSF]}
- A61K 38/20: Interleukins [IL]
- A61K 38/2013: {IL-2}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

A method of antitumor therapy is described in which administration of a chemotherapeutic drug, encapsulated in liposomes, is supplemented by administration of an immunostimulating cytokine. The cytokine is preferably also encapsulated in liposomes. In tumor models for lung and colon carcinomas, this method produced a significantly greater therapeutic effect, as evidenced by survival rate and tumor size, than a combination of the effects produced by the free or liposome-encapsulated components administered individually.

## Claims

### Claim 1

A method for antitumor therapy, comprising
administering to a subject in need of such treatment, a therapeutically effective amount of a non-encapsulated chemotherapy drug and an immunostimulating cytokine,
wherein the cytokine is encapsulated in multilamellar liposomes (MLV),
said treatment being characterized in that the subject is administered on non-consecutive days with two or more DOSES of said liposome encapsulated cytokine,
a first dose being administered at least 3 days following administration of said chemotherapeutic drug,
wherein the time between administrations is such that the therapeutic effect of the combined administrations is greater than the sum of the therapeutic effects produced by administration of said chemotherapeutic drug alone and by administration of said immunostimulating cytokine alone.

### Claim 2 (depends on 1)

The method of claim 1, wherein said cytokine is selected from the group consisting of interleukin-2 (IL-2), IL-12, IL-15, IL-18, INF-γ, INF-α, INF-β, G-CSF, and GM-CSF.

### Claim 3 (depends on 2)

The method of claim 2, wherein said cytokine is IL-2.

### Claim 4 (depends on 1)

The method of claim 1, wherein the liposomes comprise at least one lipid selected from the group consisting of dimyristoyl phosphatidyl choline (DMPC), dimyristoyl phosphatidyl glycerol (DMPG), 1,2-distearoyl-3-trimethylammonium propane (DSTAP), phosphatidyl choline, phosphatidyl ethanolamine and cholesterol.

### Claim 5 (depends on 4)

The method of claim 4, wherein said cytokine is encapsulated in liposomes comprising (1) DMPC and (2) at least one additional lipid selected from the group consisting of dimyristoyl phosphatidyl glycerol (DMPG), and 1,2-distearoyl-3-trimethylammonium propane (DSTAP), said at least one additional lipid being in an amount of up to 50%.

### Claim 6 (depends on 5)

The method of claim 5, wherein said liposome is composed of DMPC and DMPG.

### Claim 7 (depends on 6)

The method of claim 6, wherein the liposome comprise DMPC and DMPG in a molar ratio of about 9:1.

### Claim 8 (depends on 1)

The method of claim 1, wherein said chemotherapeutic drug is selected from the group consisting of a chemotherapeutic anthraquinone, cisplatin, and a topoisomerase I inhibitor.

### Claim 9 (depends on 8)

The method of claim 8, wherein said chemotherapeutic drug is doxorubicin (adriamycin).

### Claim 10

A method for antitumor therapy, comprising
administering to a subject in need of such treatment, a therapeutically effective amount of a chemotherapeutic drug encapsulated in liposomes and an immunostimulating cytokine encapsulated in MLV,
said treatment being characterized in that the subject is administered on non-consecutive days with two or more doses of said MLV encapsulated cytokine,
a first dose of said MLV encapsulated cytokine being administered at least 3 days following administration of said liposome encapsulated chemotherapeutic drug,
wherein the time between administration of said MLV encapsulated chemotherapeutic drug and said liposome encapsulated cytokine is such that the combined therapeutic effect of said administrations is greater than a sum of the therapeutic effect produced by administration of the liposome encapsulated chemotherapeutic drug alone by administration of said MLV encapsulated immunostimulating cytokine alone.

### Claim 11 (depends on 10)

The method of claim 10, wherein said cytokine is selected from the group consisting of interleukin-2 (IL-2), IL-12, IL-15, IL-18, INF-γ, INF-α, INF-β, G-CSF, and GM-CSF.

### Claim 12 (depends on 11)

The method of claim 11, wherein said cytokine is IL-2.

### Claim 13 (depends on 10)

The method of claim 10, wherein the MLV encapsulating said immunostimulating cytokine comprise at least one lipid selected from the group consisting DMPC, DMPG, DSTAP, phosphatidyl choline, phosphatidyl ethanolamine and cholesterol.

### Claim 14 (depends on 13)

The method of claim 13, wherein said cytokine is encapsulated in MLV comprising (1) DMPC and (2) at least one additional lipid selected from the group consisting of DMPG and DSTAP, said at least one additional lipid being in an amount of up to 50%.

### Claim 15 (depends on 14)

The method of claim 14, wherein said MLV comprise of DMPC and DMPG.

### Claim 16 (depends on 15)

The method of claim 15, wherein the MLV DMPC and DMPG are present in a molar ratio of about 9:1.

### Claim 17 (depends on 10)

The method of claim 10, wherein the liposomes encapsulating said chemotherapeutic drug comprise 1-10 mole percent of a lipid having a polar head group dericatized with a polyethylene glycol chain which has a molecular weight of between 750 and 10,000 dalton.

### Claim 18 (depends on 10)

The method of claim 10, wherein said chemotherapeutic drug is selected from the group consisting of a chemotherapeutic anthraquinone, cisplatin, and a topoisomerase I inhibitor.

### Claim 19 (depends on 18)

The method of claim 18, wherein said chemotherapeutic drug is doxorubicin (adriamycin).

### Claim 20 (depends on 19)

The method of claim 19, wherein said chemotherapeutic drug is polyethylene glycol-coated liposomal doxorubicin.
